Research Analysts Set Expectations for RYTM FY2025 Earnings

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) – Investment analysts at Leerink Partnrs upped their FY2025 earnings per share estimates for shares of Rhythm Pharmaceuticals in a research report issued to clients and investors on Tuesday, November 4th. Leerink Partnrs analyst F. Khurshid now expects that the company will post earnings of ($3.34) per share for the year, up from their prior forecast of ($3.41). The consensus estimate for Rhythm Pharmaceuticals’ current full-year earnings is ($4.32) per share. Leerink Partnrs also issued estimates for Rhythm Pharmaceuticals’ Q4 2025 earnings at ($0.96) EPS, Q1 2026 earnings at ($1.02) EPS, Q2 2026 earnings at ($0.97) EPS, Q3 2026 earnings at ($0.87) EPS, Q4 2026 earnings at ($0.70) EPS and FY2026 earnings at ($3.56) EPS.

Several other brokerages have also issued reports on RYTM. Guggenheim lifted their price target on Rhythm Pharmaceuticals from $119.00 to $120.00 and gave the company a “buy” rating in a report on Wednesday, August 6th. JMP Securities increased their price objective on Rhythm Pharmaceuticals from $135.00 to $142.00 and gave the stock a “market outperform” rating in a report on Thursday, September 25th. Citigroup reiterated an “outperform” rating on shares of Rhythm Pharmaceuticals in a research note on Thursday, September 25th. Morgan Stanley boosted their target price on shares of Rhythm Pharmaceuticals from $122.00 to $129.00 and gave the stock an “overweight” rating in a research report on Thursday, October 16th. Finally, Wall Street Zen lowered shares of Rhythm Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Rhythm Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $112.54.

Rhythm Pharmaceuticals Trading Up 1.8%

Shares of NASDAQ:RYTM opened at $100.30 on Friday. Rhythm Pharmaceuticals has a 1 year low of $45.90 and a 1 year high of $116.00. The business has a fifty day simple moving average of $103.00 and a 200 day simple moving average of $84.70. The firm has a market cap of $6.66 billion, a price-to-earnings ratio of -33.32 and a beta of 2.12.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last announced its earnings results on Tuesday, November 4th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.10). The firm had revenue of $51.30 million for the quarter, compared to analyst estimates of $50.71 million. Rhythm Pharmaceuticals had a negative net margin of 117.13% and a negative return on equity of 1,831.43%.

Institutional Investors Weigh In On Rhythm Pharmaceuticals

Several hedge funds have recently modified their holdings of the business. Vanguard Group Inc. grew its stake in shares of Rhythm Pharmaceuticals by 39.2% in the third quarter. Vanguard Group Inc. now owns 4,996,427 shares of the company’s stock worth $504,589,000 after acquiring an additional 1,407,313 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in Rhythm Pharmaceuticals by 51.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,188,069 shares of the company’s stock valued at $119,983,000 after purchasing an additional 404,510 shares during the period. Advisors Asset Management Inc. boosted its holdings in Rhythm Pharmaceuticals by 4.3% in the 3rd quarter. Advisors Asset Management Inc. now owns 14,178 shares of the company’s stock valued at $1,432,000 after purchasing an additional 582 shares during the period. Profund Advisors LLC grew its position in Rhythm Pharmaceuticals by 10.7% in the 3rd quarter. Profund Advisors LLC now owns 12,457 shares of the company’s stock worth $1,258,000 after purchasing an additional 1,203 shares during the last quarter. Finally, Smartleaf Asset Management LLC increased its holdings in shares of Rhythm Pharmaceuticals by 97.2% during the 3rd quarter. Smartleaf Asset Management LLC now owns 286 shares of the company’s stock worth $29,000 after purchasing an additional 141 shares during the period.

Insiders Place Their Bets

In related news, CFO Hunter C. Smith sold 24,611 shares of the business’s stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $96.33, for a total transaction of $2,370,777.63. Following the completion of the transaction, the chief financial officer owned 116,915 shares of the company’s stock, valued at approximately $11,262,421.95. The trade was a 17.39% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Joseph Shulman sold 14,437 shares of the stock in a transaction that occurred on Thursday, October 16th. The shares were sold at an average price of $112.03, for a total value of $1,617,377.11. Following the sale, the insider owned 8,509 shares of the company’s stock, valued at approximately $953,263.27. The trade was a 62.92% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 64,760 shares of company stock valued at $6,689,531 in the last quarter. Insiders own 6.10% of the company’s stock.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.